Xencor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Xencor and other ETFs, options, and stocks.

About XNCR

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. 

CEO
Bassil I. Dahiyat
CEOBassil I. Dahiyat
Employees
260
Employees260
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1997
Founded1997
Employees
260
Employees260

XNCR Key Statistics

Market cap
1.60B
Market cap1.60B
Price-Earnings ratio
-8.70
Price-Earnings ratio-8.70
Dividend yield
Dividend yield
Average volume
981.46K
Average volume981.46K
High today
$21.05
High today$21.05
Low today
$19.93
Low today$19.93
Open price
$20.21
Open price$20.21
Volume
676.07K
Volume676.07K
52 Week high
$21.96
52 Week high$21.96
52 Week low
$6.92
52 Week low$6.92

Stock Snapshot

With a market cap of 1.6B, Xencor(XNCR) trades at $20.84. The stock has a price-to-earnings ratio of -8.70.

During the trading session on 2026-08-07, Xencor(XNCR) shares reached a daily high of $21.05 and a low of $19.93. At a current price of $20.84, the stock is +4.6% higher than the low and still -1.0% under the high.

Trading volume for Xencor(XNCR) stock has reached 676.07K, versus its average volume of 981.46K.

The stock's 52-week range extends from a low of $6.92 to a high of $21.96.

The stock's 52-week range extends from a low of $6.92 to a high of $21.96.

XNCR News

Simply Wall St 18h
Xencor Stock Drifts As Revenue Lands But Profit Path Stays Murky - simplywall.st

...

Xencor Stock Drifts As Revenue Lands But Profit Path Stays Murky - simplywall.st
Simply Wall St 1d
Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?

Xencor, Inc. has reported its second-quarter and half-year 2026 results, with quarterly net loss narrowing to US$21.73 million and basic loss per share from con...

Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?
TipRanks 1d
Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target

Xencor, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from Canaccord Genuity maintained a Buy rating on t...

Analyst ratings

86%

of 14 ratings
Buy
85.7%
Hold
14.3%
Sell
0%

More XNCR News

TipRanks 1d
Xencor price target raised to $20 from $19 at RBC Capital

RBC Capital raised the firm’s price target on Xencor (XNCR) to $20 from $19 and keeps an Outperform rating on the shares. Unlock powerful investing tools with...

Simply Wall St 4d
Xencor Could Be 29% Undervalued Following Its Sharp Single Day Move

Xencor (XNCR) has drawn investor attention after a sharp single day move, with the stock closing at US$20.21. Recent trading comes against a backdrop of mixed l...

Xencor Could Be 29% Undervalued Following Its Sharp Single Day Move
TipRanks 4d
Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

Xencor Inc. (XNCR) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

TipRanks 4d
Xencor Expands Plamotamab Into Rheumatoid Arthritis: What Early Trial Progress Means for Investors

Xencor Inc. (XNCR) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

People also own

Based on the portfolios of people who own XNCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.